Hydromorphone Injection Recalled Due to Presence of Sulfite
While no adverse events have been reported to date, the use of this product could potentially cause serious adverse reactions.
All articles by Diana Ernst, RPh
FDA Draft Guidance Seeks to Improve Drug Abuse, Dependence Information in Labeling
The FDA is looking to make the information in the Drug Abuse and Dependence section of product labeling more consistent and clear through a new draft guidance.
Review Investigates Adverse Effects of Cannabidiol
The use of cannabidiol (CBD), the non-intoxicating component of cannabis, has been associated with numerous adverse effects based on available evidence from animal and human studies.
Loteprednol Etabonate Now Available for Postoperative Ocular Pain
Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% has been made available by Bausch + Lomb for the treatment of postoperative inflammation and pain following ocular surgery.
Lotemax SM Approved for Post-Op Inflammation, Pain Following Ocular Surgery
The Food and Drug Administration (FDA) has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38% for the treatment of postoperative inflammation and pain following ocular surgery.
Chronic Low Back Pain Study Results Indicate Benefit With Tanezumab
Tanezumab, an investigational subcutaneously-administered, non-opioid treatment, may benefit patients with moderate to severe chronic low back pain (CLBP), according to top-line results from a Phase 3 study.
Next post in Low Back Pain
